- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07884071
AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy (AYU-STEP)
Effect of AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy: Prospective Pilot Study
Chemotherapy-induced peripheral neuropathy (CIPN) affects approximately 40% of patients treated with taxanes. These agents may cause burning pain, paresthesia, numbness, and loss of proprioceptive sensitivity, which can reduce well-being and impair quality of life.In this context, implementing non-pharmacological interventions, such as foot treatment/manipulation proposed in this project, represents a promising area to explore complementary therapies with minimal toxicity and low cost for symptom management.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Irene Feroce
- Telefoonnummer: +39 0257489551
- E-mail: irene.feroce@ieo.it
Studie Locaties
-
-
-
Milan, Italië, 20141
- Werving
- European Institute of Oncology
-
Contact:
- Irene Feroce
- Telefoonnummer: 0257489551
- E-mail: irene.feroce@ieo.it
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 anni
- Diagnosis of carcinoma with ongoing treatment or treatment completed within the previous 6 months with taxanes (paclitaxel/docetaxel).
- Grade 1-2 sensory-motor peripheral neuropathy (NCI-CTCAE v5).
- Able to walk independently.
- Written informed consent.
Exclusion Criteria:
- Pre-existing diabetic neuropathy
- Foot ulcers or infections
- Central neurological disorders
- Concomitant specific treatment for CINP including other complementary medicine. Occasional over the counter drugs such as NSIDs or pain killer are allowed. Any other clinical condition that, at the discretion of the physician or practitioner, may contraindicate participation in the study procedures.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment arm
Manual manipulation of the feet |
The treatment consists of manual manipulation of the feet using Mahanarayan oil. Each session lasts approximately 30-40 minutes and is performed with the patient in a supine position, including massage of the foot and lower leg. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of patients that completed the treatment
Tijdsspanne: From enrollment to the follow-up contact at 10 weeks
|
Adherence to treatment will be measured as the number of subjects that completed all study treatment sessions on the total number of subjects enrolled. |
From enrollment to the follow-up contact at 10 weeks
|
|
Incidence of local adverse events related to the use of medicated oils during treatement sessions or manual therapy.
Tijdsspanne: From enrollment to the follow-up contact at 10 weeks
|
Incidence will be calculated as the number of local adverse events related to the use of medicated oils during treatement sessions or manual therapy on the total number of treatment sessions administered. |
From enrollment to the follow-up contact at 10 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline in the score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale (QLQ-CIPN20) at 10 weeks.
Tijdsspanne: From enrollment to the follow-up contact at 10 weeks
|
Impact of treatment on Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the QLQ-CIPN20 questionnaire. The QLQ-CIPN20 questionnaire will be administered four times: before the first treatment, at mid-treatment, at the end of treatment, and at follow-up. Higher the resulting score mean higher the CIPN affect the patient. Impact of treatment will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
|
Change from baseline in the score of The McGill Pain Questionnaire (P.R.I.) at 10 weeks.
Tijdsspanne: From enrollment to the follow-up contact at 10 weeks
|
The McGill Pain Questionnaire (P.R.I.) will be administered before the first treatment, at the end of the treatment, and at follow-up. Higher the resulting score mean higher the paint felt by the patient. Impact of treatment on the reduction of the pain will be defined by the comparison of initial scoring and post treatment scoring. |
From enrollment to the follow-up contact at 10 weeks
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- UID 5323
- L2-657 (Andere identificatie: Comitato Etico Lombardia 2)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .